Enobosarm

DRUG5 trials

Conditions

Androgen Receptor PositiveEstrogen Receptor NegativeHER2/Neu NegativeHOMA-IRMammographic DensityMetastatic Breast CancerMetastatic Triple-Negative Breast CarcinomaMobility Disability

Phase 1

Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density

CompletedNCT03264651

Havah Therapeutics Pty LtdMammographic Density

Start: 2017-02-01End: 2018-03-21Updated: 2018-04-18

Phase 2

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

CompletedNCT02971761

City of Hope Medical CenterAndrogen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative +3

Start: 2017-06-01End: 2022-08-16Updated: 2024-02-20

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

CompletedNCT06282458

Veru Inc.Muscle Loss, Obesity

Start: 2024-04-29End: 2025-08-22Updated: 2025-09-17

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Active, not recruitingNCT07446998

Veru Inc.HOMA-IR, Mobility Disability, Obesity & Overweight

Start: 2026-03-26End: 2027-12-01Updated: 2026-09-04

Phase 3

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

TerminatedNCT04869943

Veru Inc.Metastatic Breast Cancer

Start: 2021-10-12End: 2024-01-09Updated: 2024-01-26

Related Papers

Abstract PO2-27-03: Clinical Results of Subjects Remaining in the Phase 3 ARTEST Study Enobosarm Therapy in AR+ER+HER2- Metastatic Breast Cancer with 3 or Greater Prior Lines of Therapy

Cancer Research2024-05-02

Abstract P5-06-26: Gut microbiome profiling of patients with metastatic breast cancer undergoing immune checkpoint inhibitor therapy

Cancer Research2020-02-152 citations

A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer.

Journal of Clinical Oncology2019-05-208 citations